JP2021502329A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021502329A5 JP2021502329A5 JP2020520153A JP2020520153A JP2021502329A5 JP 2021502329 A5 JP2021502329 A5 JP 2021502329A5 JP 2020520153 A JP2020520153 A JP 2020520153A JP 2020520153 A JP2020520153 A JP 2020520153A JP 2021502329 A5 JP2021502329 A5 JP 2021502329A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- cancer
- items
- agent
- biologically active
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 description 50
- 206010028980 Neoplasm Diseases 0.000 description 34
- 201000011510 cancer Diseases 0.000 description 33
- 210000004027 cell Anatomy 0.000 description 27
- 108090000765 processed proteins & peptides Proteins 0.000 description 25
- 229920001184 polypeptide Polymers 0.000 description 23
- 102000004196 processed proteins & peptides Human genes 0.000 description 23
- 239000003795 chemical substances by application Substances 0.000 description 22
- 101150111584 RHOA gene Proteins 0.000 description 16
- 102100022387 Transforming protein RhoA Human genes 0.000 description 16
- 239000012634 fragment Substances 0.000 description 16
- 150000007523 nucleic acids Chemical class 0.000 description 12
- 238000009169 immunotherapy Methods 0.000 description 10
- 230000004083 survival effect Effects 0.000 description 7
- 102000038594 Cdh1/Fizzy-related Human genes 0.000 description 6
- 108091007854 Cdh1/Fizzy-related Proteins 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 238000000423 cell based assay Methods 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 238000011275 oncology therapy Methods 0.000 description 6
- -1 ICOS Proteins 0.000 description 4
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 4
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 208000024334 diffuse gastric cancer Diseases 0.000 description 4
- 230000007705 epithelial mesenchymal transition Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 3
- JPSHPWJJSVEEAX-OWPBQMJCSA-N (2s)-2-amino-4-fluoranylpentanedioic acid Chemical compound OC(=O)[C@@H](N)CC([18F])C(O)=O JPSHPWJJSVEEAX-OWPBQMJCSA-N 0.000 description 2
- 102100023990 60S ribosomal protein L17 Human genes 0.000 description 2
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 2
- 108010074708 B7-H1 Antigen Proteins 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 206010055113 Breast cancer metastatic Diseases 0.000 description 2
- 102100024263 CD160 antigen Human genes 0.000 description 2
- 102100038078 CD276 antigen Human genes 0.000 description 2
- 102100036008 CD48 antigen Human genes 0.000 description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 2
- 102100035943 HERV-H LTR-associating protein 2 Human genes 0.000 description 2
- 108010007712 Hepatitis A Virus Cellular Receptor 1 Proteins 0.000 description 2
- 102100034459 Hepatitis A virus cellular receptor 1 Human genes 0.000 description 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 2
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 2
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 2
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 description 2
- 101000716130 Homo sapiens CD48 antigen Proteins 0.000 description 2
- 101001021491 Homo sapiens HERV-H LTR-associating protein 2 Proteins 0.000 description 2
- 101000984190 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 1 Proteins 0.000 description 2
- 101000984189 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 2 Proteins 0.000 description 2
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 description 2
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 2
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 2
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 description 2
- 102100034980 ICOS ligand Human genes 0.000 description 2
- 102000002698 KIR Receptors Human genes 0.000 description 2
- 108010043610 KIR Receptors Proteins 0.000 description 2
- 102000017578 LAG3 Human genes 0.000 description 2
- 101150030213 Lag3 gene Proteins 0.000 description 2
- 102100025584 Leukocyte immunoglobulin-like receptor subfamily B member 1 Human genes 0.000 description 2
- 102100025583 Leukocyte immunoglobulin-like receptor subfamily B member 2 Human genes 0.000 description 2
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 description 2
- 206010050017 Lung cancer metastatic Diseases 0.000 description 2
- 102000012220 Member 14 Tumor Necrosis Factor Receptors Human genes 0.000 description 2
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 2
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 2
- 102100029527 Natural cytotoxicity triggering receptor 3 ligand 1 Human genes 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 2
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 101150036449 SIRPA gene Proteins 0.000 description 2
- 102100039367 T-cell immunoglobulin and mucin domain-containing protein 4 Human genes 0.000 description 2
- 101710174757 T-cell immunoglobulin and mucin domain-containing protein 4 Proteins 0.000 description 2
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 2
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 2
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 description 2
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 229940022399 cancer vaccine Drugs 0.000 description 2
- 238000009566 cancer vaccine Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762583166P | 2017-11-08 | 2017-11-08 | |
| US62/583,166 | 2017-11-08 | ||
| PCT/US2018/059188 WO2019094326A1 (en) | 2017-11-08 | 2018-11-05 | Compositions and methods for treating cancer using rhoa dominant negative forms |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021502329A JP2021502329A (ja) | 2021-01-28 |
| JP2021502329A5 true JP2021502329A5 (https=) | 2021-12-16 |
Family
ID=66439269
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020520153A Pending JP2021502329A (ja) | 2017-11-08 | 2018-11-05 | Ｒｈｏａドミナントネガティブフォームを使用して癌を治療するための組成物および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11957739B2 (https=) |
| EP (1) | EP3706751A4 (https=) |
| JP (1) | JP2021502329A (https=) |
| CN (1) | CN111278443A (https=) |
| AU (1) | AU2018365800A1 (https=) |
| CA (1) | CA3076269A1 (https=) |
| WO (1) | WO2019094326A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111278443A (zh) | 2017-11-08 | 2020-06-12 | 丹娜法伯癌症研究院 | 使用rhoa显性负型治疗癌症的组合物和方法 |
| SE2000055A1 (sv) * | 2020-03-15 | 2021-09-16 | Martin Ivanov Denev | Användande av fotohydrauliskt mekanisk chock, för selektiv sprängning av relativ svagare cellmembranen av cancerceller, vilka har svagare cellmembran än friska celler |
| CN113278706B (zh) * | 2021-07-23 | 2021-11-12 | 广州燃石医学检验所有限公司 | 一种用于区分体细胞突变和种系突变的方法 |
| WO2024059823A1 (en) * | 2022-09-15 | 2024-03-21 | Iview Therapeutics, Inc. | Self-complementary AAV vectors carrying dominant negative RhoA and methods of use to treat ocular diseases |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010044414A1 (en) * | 1999-12-10 | 2001-11-22 | Whitehead Institute For Biomedical Research | Metastasis genes and uses thereof |
| WO2003030836A2 (en) * | 2001-10-12 | 2003-04-17 | Case Western Reserve University | Neuronal regeneration |
| US20050209147A1 (en) * | 2004-01-16 | 2005-09-22 | The Board Of Trustees Of The Leland Stanford Junior University | Peptide inhibitors of RhoA signaling |
| US7951924B2 (en) * | 2004-11-12 | 2011-05-31 | University Of South Florida | RhoB variants and methods of use |
| US7507534B2 (en) * | 2005-09-01 | 2009-03-24 | National Health Research Institutes | Rapid efficacy assessment method for lung cancer therapy |
| US20070161060A1 (en) * | 2005-09-07 | 2007-07-12 | Anderson Richard A | Screening method for identifying an agent that modulates PIPKIgamma trafficking of E-cadherin |
| US9163077B2 (en) * | 2007-12-19 | 2015-10-20 | Rhovac Aps | RhoC-based immunotherapy |
| WO2009089040A1 (en) * | 2008-01-11 | 2009-07-16 | Jaffrey Samie R | Methods for expressing proteins in axons |
| EP2274617A4 (en) * | 2008-04-10 | 2011-11-09 | Massachusetts Inst Technology | METHOD OF DETECTING AND USING MEDIUM-TREATMENT AID ON CANCER STEM CELLS |
| NZ713461A (en) * | 2011-04-15 | 2017-02-24 | Compugen Ltd | Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer |
| TWI595006B (zh) * | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| CN111278443A (zh) | 2017-11-08 | 2020-06-12 | 丹娜法伯癌症研究院 | 使用rhoa显性负型治疗癌症的组合物和方法 |
-
2018
- 2018-11-05 CN CN201880066812.2A patent/CN111278443A/zh active Pending
- 2018-11-05 CA CA3076269A patent/CA3076269A1/en active Pending
- 2018-11-05 WO PCT/US2018/059188 patent/WO2019094326A1/en not_active Ceased
- 2018-11-05 EP EP18875691.0A patent/EP3706751A4/en not_active Withdrawn
- 2018-11-05 AU AU2018365800A patent/AU2018365800A1/en not_active Abandoned
- 2018-11-05 US US16/761,540 patent/US11957739B2/en active Active
- 2018-11-05 JP JP2020520153A patent/JP2021502329A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sahin et al. | An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma | |
| Lhuillier et al. | Radiotherapy-exposed CD8+ and CD4+ neoantigens enhance tumor control | |
| Buqué et al. | Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer | |
| ES2988795T3 (es) | Composiciones, artículos de fabricación y métodos relacionados con la dosificación en terapia celular | |
| CN104427992B (zh) | 生物标志物及使用溶瘤病毒和免疫调节剂的组合疗法 | |
| JP6945444B2 (ja) | 高親和性ｐｄ−１薬剤とその使用方法 | |
| JP7564122B2 (ja) | 光免疫療法のための方法および関連バイオマーカー | |
| JP2021155442A (ja) | Ｎａｎｔ癌ワクチン | |
| Meraz et al. | TUSC2 immunogene therapy synergizes with anti–PD-1 through enhanced proliferation and infiltration of natural killer cells in syngeneic Kras-mutant mouse lung cancer models | |
| JP2021520849A (ja) | 腫瘍特異的ｔ細胞受容体を得る方法 | |
| JP2020514378A (ja) | 処置方法 | |
| US11219676B2 (en) | Methods of cancer treatment using tumor antigen-specific T cells | |
| CN110072550A (zh) | 用于治疗脑癌的组合疗法 | |
| JP2021502329A5 (https=) | ||
| Zhang et al. | In situ sting‐activating nanovaccination with tigit blockade for enhanced immunotherapy of anti‐Pd‐1‐resistant tumors | |
| TW201718852A (zh) | 具有病患衍生之異種移植物之非ｈｌａ配對的人源化ｎｓｇ小鼠模式 | |
| TW201742923A (zh) | 用於新抗原表位呈現的序列安排及序列 | |
| JP7851251B2 (ja) | 遺伝子サンプリングにおける統計的バイアスの軽減 | |
| US20240110230A1 (en) | Biomarkers for cancer treatment | |
| TW202320842A (zh) | 用於治療黑色素瘤之組合物及方法 | |
| JP2020524149A5 (https=) | ||
| WO2018148378A1 (en) | Modulating biomarkers to increase tumor immunity and improve the efficiacy of cancer immunotherapy | |
| CN111148518A (zh) | 使用cdk4/6抑制剂调控调节性t细胞和免疫应答的方法 | |
| US20230295734A1 (en) | Bcor rearrangements and uses thereof | |
| CN115803824A (zh) | 鉴定与临床反应相关的特征的方法及其用途 |